Gates Foundation Strategic Investment Fund Logo
Share this page:

Press Release: Genocea announces $1.2 million grant for malaria vaccine discovery


September 23, 2014

Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria vaccines.

The grant, which extends Genocea’s existing malaria collaboration with the Gates Foundation through 2015, supports comprehensive screening of the malaria proteome to identify targets of protective T cell responses. The Gates Foundation also invested in Genocea in its Series C funding round in 2012.

Read the full text here.